Latest Breaking News On - Affamed therapeutics - Page 4 : comparemela.com

Taking Stock of Current and Emerging Anti-VEGF Therapy Dosing Regimens for nAMD

Comparing Innoviva (NASDAQ:INVA) & Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix (NASDAQ:OCUL – Free Report) and Innoviva (NASDAQ:INVA – Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations. Risk & Volatility Ocular Therapeutix has a beta of 1.22, […]

Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema

/PRNewswire/ Allgenesis Biotherapeutics Inc., a clinical-stage specialty pharmaceutical company focused on developing novel ophthalmic drugs, announces.

AffaMed Technologies Announces the First Implantation in the China Registrational Clinical Trial of MINI WELL®, the Progressive Extended Depth-of-Focus IOL

/PRNewswire/ AffaMed Technologies ("AffaMed"), a joint venture established between AffaMed Therapeutics and SIFI S.p.A., today announced the completion of.

AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention in Mainland China

/PRNewswire/ AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to address critical unmet medical needs in.